Alkermes plc (FRA:8AK)

Market Cap	4.79B +7.6%
Revenue (ttm)	1.26B -5.2%
Net Income	205.83M -34.2%
EPS	1.22 -34.1%
Shares Out	n/a
PE Ratio	23.26
Forward PE	17.06
Dividend	n/a
Ex-Dividend Date	n/a

Volume	80
Average Volume	13
Open	28.24
Previous Close	28.26
Day's Range	28.24 - 28.24
52-Week Range	22.00 - 30.20
Beta	n/a
RSI	54.37
Earnings Date	May 5, 2026

About Alkermes

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramu...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 2,050
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8AK

Financial Performance

In 2025, Alkermes's revenue was $1.48 billion, a decrease of -5.25% compared to the previous year's $1.56 billion. Earnings were $241.66 million, a decrease of -34.16%.

Financial numbers in USD